A post-marketing registry-based prospective cohort study of long-term safety of risankizumab in Denmark and Sweden

ENCePP Code of conduct

Yes

Data sources

• Data source(s):
  Danish registries (access/analysis)

  Sweden National Prescribed Drugs Register / Läkemedelsregistret

  Sweden National Cancer Register / Cancerregistret

  Swedish Cause of Death Register
• Data source(s), other:
  The Swedish National Patient Register Sweden; Swedish Registry for Systemic Psoriasis Treatment (PsoReg);
• Data sources (types):
  Cancer registry

  Death registry

  Disease registry

  Pharmacy dispensing records

  Population registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No